Decreased Expression of Circulating miR-20a-5p in South African Women with Gestational Diabetes Mellitus

Pheiffer, Carmen; Dias, Stephanie; Rheeder, Paul; Adam, Sheryl

doi:10.1007/s40291-018-0325-0

Cited by 64 publications

(94 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, most of microRNAs, which were the subjects of our interest, have not yet been observed by other investigators to be dysregulated in maternal circulation (peripheral blood, plasma, or serum samples) of women with clinically established GDM or before the onset of GDM [20,21,37,80,92,143,149,[172][173][174][175][176]. So, it is feasible that epigenetic profiles of a series of microRNAs have also been changing with time by force of various circumstances as a result of the interaction between genetic and environmental factors [177].…”

Section: Discussionmentioning

confidence: 87%

“…To the best of our present knowledge, no study on expression profiling of microRNAs associated with diabetes mellitus, and cardiovascular and cerebrovascular diseases in whole peripheral blood of mothers after pregnancies affected by gestational diabetes mellitus has been carried out. [11] Acute myocardial infarction, heart ischemia, post-myocardial infarction complications [12], diabetes mellitus [13,14], vascular endothelial dysfunction [15] hsa-miR-16-5p 13q14.2 Myocardial infarction [16,17], heart failure [18], acute coronary syndrome, cerebral ischaemic events [19], gestational diabetes mellitus [20,21], diabetes mellitus [22][23][24] hsa-miR-17-5p 13q31.3 [25,26] Cardiac development [27], ischemia/reperfusion-induced cardiac injury [28], kidney ischemia-reperfusion injury [29], diffuse myocardial fibrosis in hypertrophic cardiomyopathy [30], acute ischemic stroke [31], coronary artery disease [32], adipogenic differentiation [33], gestational diabetes mellitus [20,21], diabetes mellitus [24,34] hsa-miR-20a-5p 13q31.3 [35] Pulmonary hypertension [36], gestational diabetes mellitus [20,21,37], diabetic retinopathy [38], diabetes with abdominal aortic aneurysm [39] hsa-miR-20b-5p Xq26.2 [35] Hypertension-induced heart failure [40], insulin resistance [41], T2DM [42,…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diabetes Mellitus and Cardiovascular Risk Assessment in Mothers with a History of Gestational Diabetes Mellitus Based on Postpartal Expression Profile of MicroRNAs Associated with Diabetes Mellitus and Cardiovascular and Cerebrovascular Diseases

Hromadníková

Dvořáková

Krofta

2020

IJMS

View full text Add to dashboard Cite

Mothers with a history of gestational diabetes mellitus (GDM) have an increased risk of developing diabetes in the future and a lifelong cardiovascular risk. Postpartal expression profile of cardiovascular/cerebrovascular disease associated microRNAs was assessed 3–11 years after the delivery in whole peripheral blood of young and middle-aged mothers with a prior exposure to GDM with the aim to identify a high-risk group of mothers at risk of later development of diabetes mellitus and cardiovascular/cerebrovascular diseases who would benefit from implementation of early primary prevention strategies and long-term follow-up. The hypothesis of the assessment of cardiovascular risk in women was based on the knowledge that a series of microRNAs play a role in the pathogenesis of diabetes mellitus and cardiovascular/cerebrovascular diseases. Abnormal expression profile of multiple microRNAs was found in women with a prior exposure to GDM (miR-1-3p, miR-16-5p, miR-17-5p, miR-20a-5p, miR-20b-5p, miR-21-5p, miR-23a-3p, miR-24-3p, miR-26a-5p, miR-29a-3p, miR-100-5p, miR-103a-3p, miR-125b-5p, miR-126-3p, miR-130b-3p, miR-133a-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-181a-5p, miR-195-5p, miR-199a-5p, miR-221-3p, miR-342-3p, miR-499a-5p, and-miR-574-3p). Postpartal combined screening of miR-1-3p, miR-16-5p, miR-17-5p, miR-20b-5p, miR-21-5p, miR-23a-3p, miR-26a-5p, miR-29a-3p, miR-103a-3p, miR-133a-3p, miR-146a-5p, miR-181a-5p, miR-195-5p, miR-199a-5p, miR-221-3p, and miR-499a-5p showed the highest accuracy for the identification of mothers with a prior exposure to GDM at a higher risk of later development of cardiovascular/cerebrovascular diseases (AUC 0.900, p < 0.001, sensitivity 77.48%, specificity 93.26%, cut off >0.611270413). It was able to identify 77.48% mothers with an increased cardiovascular risk at 10.0% FPR. Any of changes in epigenome (upregulation of miR-16-5p, miR-17-5p, miR-29a-3p, and miR-195-5p) that were induced by GDM-complicated pregnancy are long-acting and may predispose mothers affected with GDM to later development of diabetes mellitus and cardiovascular/cerebrovascular diseases. In addition, novel epigenetic changes (upregulation of serious of microRNAs) appeared in a proportion of women that were exposed to GDM throughout the postpartal life. Likewise, a previous occurrence of either GH, PE, and/or FGR, as well as a previous occurrence of GDM, is associated with the upregulation of miR-1-3p, miR-17-5p, miR-20a-5p, miR-20b-5p, miR-29a-3p, miR-100-5p, miR-125b-5p, miR-126-3p, miR-130b-3p, miR-133a-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-181a-5p, miR-199a-5p, miR-221-3p, and miR-499a-5p. On the other hand, upregulation of miR-16-5p, miR-21-5p, miR-23a-3p, miR-24-3p, miR-26a-5p, miR-103a-3p, miR-195-5p, miR-342-3p, and miR-574-3p represents a unique feature of aberrant expression profile of women with a prior exposure to GDM. Screening of particular microRNAs may stratify a high-risk group of mothers with a history of GDM who might benefit from implementation of early primary prevention strategies.

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Introductionmentioning

confidence: 99%

Diabetes Mellitus and Cardiovascular Risk Assessment in Mothers with a History of Gestational Diabetes Mellitus Based on Postpartal Expression Profile of MicroRNAs Associated with Diabetes Mellitus and Cardiovascular and Cerebrovascular Diseases

Hromadníková

Dvořáková

Krofta

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…More recently, Pheiffer et al reported conflicting results. The expression of all five miRNAs were decreased in South African women with GDM, however, only the decreased expression of miR-20a was statistically significant [75]. Interestingly, regression analysis showed that miR-20a was a significant predictor of GDM, while age and body mass index were not.…”

Section: Micrornas Pregnancy and Gestational Diabetesmentioning

confidence: 85%

“…reported that the expression of miR-29a, miR-132 and miR-222 were similarly decreased in the serum of South African women with GDM, however, only the latter was statistically significant [75]. Conflictingly, Tagoma et al showed that miR-222 was increased in plasma of women with GDM compared to normoglycaemic pregnancies [76].…”

Section: Micrornas Pregnancy and Gestational Diabetesmentioning

confidence: 97%

Screening for Gestational Diabetes Mellitus: The Potential of MicroRNAs

Dias¹,

Rheeder²,

Adam³

2020

Gestational Diabetes Mellitus - An Overview With Some Recent Advances

Self Cite

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is associated with short-and long-term complications in both mothers and their offspring. Screening and early diagnosis of GDM is advocated as a strategy to prevent adverse pregnancy outcomes. However, there is currently no test that is amenable to routine screening, particularly in low-and middle-income countries. MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression post-transcriptionally. In recent years, miRNAs have been the focus of increasing research due to their important role in regulating biological pathways and their aberrant expression during disease. The discovery of circulating miRNAs in maternal blood, and their altered expression during pregnancy-associated complications have increased interest into their potential as diagnostic biomarkers for GDM. In this review, we summarise studies that have investigated miRNAs in maternal blood thus providing an update of the current status of miRNAs as biomarkers for GDM. We also discuss the challenges of miRNA profiling, and highlight perspectives and recommendations for research.

show abstract

“…The levels of miRNAs in peripheral blood are affected by multiple factors. In addition to sex, ethnicity, inflammatory factors, and lifestyle (Fan et al, 2015;Wagner et al, 2016;Pheiffer et al, 2018;Ludwig et al, 2019), they may also vary among sample types (whole blood, serum, and plasma; Blondal et al, 2013). Ex-miRNAs effectively avoid the above problems due to their stable expression, and the development and application of high-throughput sequencing technology to miRNA expression profiles have greatly improved diagnostic sensitivity (Cheng et al, 2013;Chen et al, 2017).…”

Section: Circulating Ex-mirnas As Biomarkers In Nddsmentioning

confidence: 99%

Circulating Exosomal miRNA as Diagnostic Biomarkers of Neurodegenerative Diseases

Wang

Zhang

2020

Front. Mol. Neurosci.

102

View full text Add to dashboard Cite

Neurodegenerative diseases (NDDs) are a group of diseases caused by chronic and progressive degeneration of neural tissue. The main pathological manifestations are neuronal degeneration and loss in the brain and/or spinal cord. Common NDDs include Alzheimer disease (AD), Parkinson disease (PD), Huntington disease (HD), and amyotrophic lateral sclerosis (ALS). The complicated pathological characteristics and different clinical manifestations of NDDs result in a lack of sensitive and efficient diagnostic methods. In addition, no sensitive biomarkers are available to monitor the course of NDDs, predict their prognosis, and monitor the therapeutic response. Despite extensive research in recent years, analysis of amyloid β (Aβ) and α-synuclein has failed to effectively improve NDD diagnosis. Although recent studies have indicated circulating miRNAs as promising diagnostic biomarkers of NDDs, the miRNA in the peripheral circulation is susceptible to interference by other components, making circulating miRNA results less consistent. Exosomes are small membrane vesicles with a diameter of approximately 30-100 nm that transport proteins, lipids, mRNA, and miRNA. Because recent studies have shown that exosomes have a double-membrane structure that can resist ribonuclease in the blood, giving exosomal miRNA high stability and making them resistant to degradation, they may become an ideal biomarker of circulating fluids. In this review, we discuss the applicability of circulating exosomal miRNAs as biomarkers, highlight the technical aspects of exosomal miRNA analysis, and review studies that have used circulating exosomal miRNAs as candidate diagnostic biomarkers of NDDs.

show abstract

Decreased Expression of Circulating miR-20a-5p in South African Women with Gestational Diabetes Mellitus

Cited by 64 publications

References 40 publications

Diabetes Mellitus and Cardiovascular Risk Assessment in Mothers with a History of Gestational Diabetes Mellitus Based on Postpartal Expression Profile of MicroRNAs Associated with Diabetes Mellitus and Cardiovascular and Cerebrovascular Diseases

Diabetes Mellitus and Cardiovascular Risk Assessment in Mothers with a History of Gestational Diabetes Mellitus Based on Postpartal Expression Profile of MicroRNAs Associated with Diabetes Mellitus and Cardiovascular and Cerebrovascular Diseases

Screening for Gestational Diabetes Mellitus: The Potential of MicroRNAs

Circulating Exosomal miRNA as Diagnostic Biomarkers of Neurodegenerative Diseases

Contact Info

Product

Resources

About